Botulinum toxin type A in chronic migraine

References

• Zwart JA, Bovim G, Sand T, Sjaastad O. Tension type headache: botulinum toxin paralysis of temporal muscles. Headache34, 458–462 (1994).
   PubMed Web of Science ®Google Scholar
• Krack P, Hornig C, Dorndorf W. Resolution of chronic tension type headache after botulinum toxin treatment of idiopathic blepharospasm. Mov. Disord.10, 388 (1995).
   Google Scholar
• Binder WJ, Brin MF, Blitzer A, Schoenrock LD. Botulinum toxin type A (BOTOX) for the treatment of migraine headaches: an open label study. Otolaryngol. Head Neck Surg.123, 669–676 (2000).
   PubMed Web of Science ®Google Scholar
• Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity and immunology. Muscle Nerve (Suppl. 6), S146–S168 (1997).
   Google Scholar
• Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur. J. Neurol.13(Suppl. 1), 2–10 (2006).
   PubMed Web of Science ®Google Scholar
• Rosales RI, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerve19, 488–496 (1996).
   PubMed Web of Science ®Google Scholar
• Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum toxin effects on rat jaw muscle spindles. Acta Otolaryngol.113, 400–404 (1993).
   PubMed Web of Science ®Google Scholar
• Wiegand H, Wellhoner HH. The action of botulinum a neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch. Pharmacol.298, 235–238 (1977).
   PubMed Web of Science ®Google Scholar
• Wiegand H, Erdmann G, Wellhoner HH. I125-labeled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch. Pharmacol.292, 161–165 (1976).
   PubMed Web of Science ®Google Scholar
• Aoki R. The development of BOTOX – its history and pharmacology. Pain Digest8, 337–341 (1998).
   Google Scholar
• Iskawa H, Mitsui Y, Yoshitomi T. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J. Opthalmol.44, 106–109 (2000).
   PubMedGoogle Scholar
• Van den Bergh P, De Beukelaer M, Deconinek N. Effect of muscle denervation on the expression of substance P in the ventral raphe-spinal pathway of the rat. Brain Res.707, 206–212 (1996).
   PubMedGoogle Scholar
• Humm Am, Pabst C, Lauterberg T, Burgunder JM. Enkephalin and aFGF are differentially regulated in the rat spinal motor neurons after chemodenervation with botulinum toxin. Exp. Neurol.161, 361–372 (2000).
   PubMedGoogle Scholar
• Cui M, Aoki KR. Botulinum toxin type A reduces inflammatory pain the rat formalin model. Cephalalgia20, 414 (2000).
   Google Scholar
• Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology26, 785–793 (2005).
   PubMed Web of Science ®Google Scholar
• Park HJ, Lee Y, Lee J, Park C, Moon DE. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can. J. Anaesth.53, 470–477 (2006).
   PubMedGoogle Scholar
• Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain122, 315–325 (2006).
   PubMedGoogle Scholar
• Kim DY, Oh BM, Paik NJ. Central effect of botulinum toxin type A in humans. Int. J. Neurosci.116, 667–680 (2006).
   PubMed Web of Science ®Google Scholar
• Olesen J, Bousser M-G, Diener H-C et al. Headache Classification Committee: new appendix criteria open for a broader concept of chronic migraine. Cephalalgia26, 742–746 (2006).
   PubMed Web of Science ®Google Scholar
• Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain106, 81–89 (2003).
   PubMed Web of Science ®Google Scholar
• Buchgreitz L, Lyngberg AC, Bendtsen L, Jensen R. Frequency of headache is related to sensitization: a population study. Pain123, 19–27 (2006).
   PubMed Web of Science ®Google Scholar
• Jakubowski M, Silberstein S, Ashkenazi A, Burstein R. Can Allodynic migraine patients be identified interictally using a questionnaire? Neurology65, 1419–1422 (2005).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology63, 848–852 (2004).
   PubMed Web of Science ®Google Scholar
• Freitag FG, Kozma CM, Slaton T, Osterhaus JT, Barron R .Characterization and prediction of emergency department use in chronic daily headache patients. Headache45, 891–898 (2005).
   PubMedGoogle Scholar
• Maizels M. Health resource utilization of the emergency department headache ‘repeater’. Headache42, 747–753 (2002).
   PubMed Web of Science ®Google Scholar
• Chan BT, Ovens HJ. Chronic migraineurs: an important subgroup of patients who visit emergency departments frequently. Ann. Emerg. Med.43, 238–242 (2004).
   PubMedGoogle Scholar
• Salomone JA, Thomas RW, Althoff JR et al. An evaluation of the role of the ED in the management of migraine headaches. Am. J. Emerg. Med.12, 134–137 (1994).
   PubMed Web of Science ®Google Scholar
• Lane PL, Nituica CM, Sorondo B. Headache patients: who does not come to the emergency department? Acad. Emer. Med.10, 528 (2003).
   Google Scholar
• Blumenthal HJ, Weisz MA, Kelly KM. Patients with primary headache disorders in the emergency department. Head. Q.11, 25–31 (2000).
   Web of Science ®Google Scholar
• Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics13, 667–676 (1998).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache43, 171–178 (2003).
   PubMed Web of Science ®Google Scholar
• Freitag FG, Diamond S, Diamond ML, Urban GJ. MIDAS as a healthcare utilization predictor in tertiary care headache management. Neurology56, A311–A312 (2001).
   Google Scholar
• Relja M, Poole AC, Schoenen J et al. A multicentre, double-blind, randomised, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of migraine headache. J. Neurol.252(Suppl. 2), 62 (2005).
   PubMedGoogle Scholar
• Silberstein SD, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache40, 445–450 (2000).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Stark SR, Lucas S, Christie S, DeGryse R, Turkel C. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc.80, 1126–1137 (2005).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache45, 293–307 (2005).
   PubMed Web of Science ®Google Scholar
• Freitag FG, Diamond S, Diamond ML, Urban GJ, Brooks KE. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Neurology66, A224 (2006).
   Google Scholar
• Saper JR, Brandes JL, Wrubel B, Dodick DW, DeGryse R, VanDenburgh AM. Efficacy of prophylactic treatment with botulinum toxin type A in migraineurs with chronic daily headache overusing acute headache pain medication. Presented at: 48th Annual Scientific Meeting of the American Headache Society. Los Angeles, CA, USA, June 23 (2006).
   Google Scholar
• Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache45, 315–324 (2005).
   PubMed Web of Science ®Google Scholar
• Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R. Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain125, 286–295 (2006).
   PubMed Web of Science ®Google Scholar
• Morgan JC, Iyer SS, Moser ET, Singer C, Sethi KD. Botulinum toxin A during pregnancy: a survey of treating physicians. J. Neurol. Neurosurg. Psychiatry77, 117–119 (2006).
   PubMed Web of Science ®Google Scholar
• Kabbouche MA, Hershey AD, Powers SW. Botulinum toxin A in the treatment of migraine headache in children. Headache45, 776–79043 (2005).
   Google Scholar
• Sarchielli P, Mancini ML, Calabresi P. Practical considerations for the treatment of elderly patients with migraine. Drugs Aging23, 461–489 (2006).
   PubMed Web of Science ®Google Scholar